Skip to main content

Sylvant Disease Interactions

There are 4 disease interactions with Sylvant (siltuximab).

Moderate

Interleukin inhibitors (applies to Sylvant) infections

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors. Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated. Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.

Switch to professional interaction data

Moderate

Siltuximab (applies to Sylvant) gastrointestinal perforation

Moderate Potential Hazard, Moderate plausibility.

The use of siltuximab may cause gastrointestinal (GI) perforation. Use with caution in patients who may be at increased risk for GI perforation. It is recommended to closely monitor patients for symptoms indicative or that may be associated with GI perforation.

Switch to professional interaction data

Moderate

Siltuximab (applies to Sylvant) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Based on a population pharmacokinetic analysis using data from clinical trials in patients, no significant difference in siltuximab clearance was observed in patients with preexisting mild to moderate hepatic impairment (Child-Pugh Class A and B, respectively) compared to patients with baseline normal hepatic function. No initial dosage adjustment is necessary for patients with mild to moderate hepatic impairment. Care should be taken when using this agent in patients with baseline severe hepatic impairment (Child-Pugh Class C) as the potential effect on siltuximab pharmacokinetics cannot be determined as clinical and pharmacokinetic data are not available.

Switch to professional interaction data

Moderate

Siltuximab (applies to Sylvant) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Based on a population pharmacokinetic analysis using data from clinical trials in patients, no significant difference in siltuximab clearance was observed in patients with preexisting renal impairment (creatinine clearance (CrCl) >=15 mL/min) compared to patients with baseline normal renal function (CrCl)>= 90 mL/min). No initial dosage adjustment is necessary for patients with CrCl >= 15 mL/min. Care should be taken when using this agent in patients with end-stage renal disease as the potential effect on siltuximab pharmacokinetics cannot be determined. Clinical monitoring of renal function is recommended.

Switch to professional interaction data

Sylvant drug interactions

There are 219 drug interactions with Sylvant (siltuximab).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer